Material News

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta024/11.11.2022/18:10) - The shareholders' meeting of Biofrontera AG on April 07, 2022 resolved to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new registered no-par value shares with a notional interest in the share capital of EUR 1.00 each (" New Shares") against cash contributions.

According to today's results, a total of 7,089,673 new shares were placed at a subscription price of EUR 1.00 each. Subscription rights were exercised for at least 6.9 million New Shares. The offer has been oversubscribed.

The gross proceeds therefore amount to EUR 7,089,673. The execution of the capital increase will be filed for registration in the Commercial Register shortly.

The funds from the capital increase should enable the Company to advance its strategic business development and market penetration as fast as possible.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20221111024 ]

Material News archive

2023

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta024/11.11.2022/18:10) - The shareholders' meeting of Biofrontera AG on April 07, 2022 resolved to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new registered no-par value shares with a notional interest in the share capital of EUR 1.00 each (" New Shares") against cash contributions.

According to today's results, a total of 7,089,673 new shares were placed at a subscription price of EUR 1.00 each. Subscription rights were exercised for at least 6.9 million New Shares. The offer has been oversubscribed.

The gross proceeds therefore amount to EUR 7,089,673. The execution of the capital increase will be filed for registration in the Commercial Register shortly.

The funds from the capital increase should enable the Company to advance its strategic business development and market penetration as fast as possible.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20221111024 ]

2022

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta024/11.11.2022/18:10) - The shareholders' meeting of Biofrontera AG on April 07, 2022 resolved to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new registered no-par value shares with a notional interest in the share capital of EUR 1.00 each (" New Shares") against cash contributions.

According to today's results, a total of 7,089,673 new shares were placed at a subscription price of EUR 1.00 each. Subscription rights were exercised for at least 6.9 million New Shares. The offer has been oversubscribed.

The gross proceeds therefore amount to EUR 7,089,673. The execution of the capital increase will be filed for registration in the Commercial Register shortly.

The funds from the capital increase should enable the Company to advance its strategic business development and market penetration as fast as possible.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20221111024 ]

2021

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta024/11.11.2022/18:10) - The shareholders' meeting of Biofrontera AG on April 07, 2022 resolved to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new registered no-par value shares with a notional interest in the share capital of EUR 1.00 each (" New Shares") against cash contributions.

According to today's results, a total of 7,089,673 new shares were placed at a subscription price of EUR 1.00 each. Subscription rights were exercised for at least 6.9 million New Shares. The offer has been oversubscribed.

The gross proceeds therefore amount to EUR 7,089,673. The execution of the capital increase will be filed for registration in the Commercial Register shortly.

The funds from the capital increase should enable the Company to advance its strategic business development and market penetration as fast as possible.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20221111024 ]

Ad Hoc News PDF archive

2020 (since April 2020)

PTA-Adhoc: Biofrontera AG: Biofrontera AG reports result of the capital increase resolved on April 07, 2022

Public disclosure of inside information according to article 17 MAR

Leverkusen, Germany (pta024/11.11.2022/18:10) - The shareholders' meeting of Biofrontera AG on April 07, 2022 resolved to increase the share capital of the Company by up to EUR 7,089,673 by issuing up to 7,089,673 new registered no-par value shares with a notional interest in the share capital of EUR 1.00 each (" New Shares") against cash contributions.

According to today's results, a total of 7,089,673 new shares were placed at a subscription price of EUR 1.00 each. Subscription rights were exercised for at least 6.9 million New Shares. The offer has been oversubscribed.

The gross proceeds therefore amount to EUR 7,089,673. The execution of the capital increase will be filed for registration in the Commercial Register shortly.

The funds from the capital increase should enable the Company to advance its strategic business development and market penetration as fast as possible.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor Relations
phone: +49 (0) 214 87 63 20
e-mail: ir@biofrontera.com
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate
other stock exchanges: US OTC

[ source: https://www.pressetext.com/news/20221111024 ]